Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.50
Bid: 5.25
Ask: 5.75
Change: -0.125 (-2.22%)
Spread: 0.50 (9.524%)
Open: 5.625
High: 5.625
Low: 5.375
Prev. Close: 5.625
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: IPF Rises As June Collections Improve

Fri, 10th Jul 2020 10:43

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - WINNERS

----------

Barclays, up 1.2%. Investec raised the lender to Buy from Hold.

----------

FTSE 250 - WINNERS

----------

Petropavlovsk, up 3.0%. The gold miner said Non-Executive Chair Peter Hambro, Chief Executive Alya Samokhvalova, Non-Executive Directors Johnny Smith, Martin Smith and Angelica Phillips will remain directors of the firm after the court requested a full hearing of Everest Alliance Ltd's application to remove them from their roles. Petropavlovsk said that while the judge found that Everest's complaints that the directors were not validly appointed were arguable, he declined to determine its application summarily and instead now requires a full hearing of Everest's application. Earlier on Friday, Everest - which has a 7.5% stake - requisitioned a general meeting to propose the hire of two new directors. The resolutions to be put forth at the meeting requested include the appointment of Paul Bushell and Ivan Kulakov as directors, the re-hire of James Cameron, Charlotte Phillipps, Katia Ray and Maxim Kharin in the event they have been removed as directors. Everest is looking to remove Hambro, Samokhvalova, Johnny Smith, Martin Smith and Phillips from the board. Everest also wants the removal of any other director that may have been appointed since Thursday until the end of the requisitioned meeting.

----------

FTSE 250 - LOSERS

----------

Senior, down 2.8%. The technology components manufacturer expressed a confident outlook going forward despite expecting to report a revenue fall in the first half of 2020. Senior reported a "robust" cash performance in the six months to the end of June, with GBP3 million net cash inflow generated during the period, in the face of "significant disruption" to its end markets. The company said it now expects revenue in the first half of 2020 to be around 30% lower than GBP580.4 million generated in the first half of 2019. Senior said net debt is expected to be GBP239 million at June 30, an improvement of GBP3 million from the end of December 2019. In 2019, in order to counter the anticipated decline in sales, Senior initiated a restructuring plan. Reflecting the additional actions which the company is taking, it now expects the total restructuring charge to be up to GBP35 million, an increase from the GBP23 million originally anticipated. Going forward, Senior said trading for the rest of 2020 continues to be hurt by Covid-19. As a result, guidance for 2020 remains suspended.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Marston's, up 2.5%. JPMorgan resumed the brewer with Neutral.

----------

International Personal Finance, up 15%. The home credit business said it is "well-placed" going forward as its collections effectiveness continued to improve in June. The company said it is encouraged by the extent to which the company is now stabilising into a "new normal" operational environment. International Personal Finance said collections effectiveness continued to improve in June, reaching 88% of pre-Covid expectations. It was at 76% in April and 80% in May. Going forward, the company said it expects collections effectiveness to progressively improve in the coming months. International Personal Finance said there is a continuing strong demand for its products. As lockdown restrictions are progressively relaxed and the company's collections effectiveness is improved, it said it has increased credit issued. In June, the company lent 37% of pre-Covid expectations, up from 30% during both of April and May.

----------

SRT Marine Systems, up 19%. The maritime surveillance provider announced the resumption of its Philippines fisheries management system project, with a significant cash payment being received in the week. The revised Philippines project plan agreed with SRT's customer is looking to accelerate implementation to make up for as much time lost as possible due to the five month pause. Meanwhile, in the Middle East final contract negotiations have recommenced and subject to completion of internal processes, these are expected to conclude soon with the projects starting in the coming months. Finally, SRT's Transcievers business has performed better than expected despite the current circumstances, achieving gross sales in the first quarter ended June 30 up 2% from the same period the year before.

----------

Focusrite, up 6.1%. The AIM-listed music & audio products company said revenue and profit are currently ahead of the company's expectations for the year to the end of August. Focusrite noted that the demand for its Audio Engineering and ADAM Audio products has been strong during the widespread lockdowns that have occurred as a result of Covid-19, thanks to widespread availability globally through e-commerce platforms. In addition, consumer registrations of products primarily focused on home recording equipment have risen. Conversely, demand for Martin Audio products has been significantly lower than pre-Covid levels of expectation due to the suspension of live music tours and festivals, although demand is now starting to show modest signs of recovery driven by the installed sound segment. Similarly, Focusrite Pro has seen muted performance as well, although the pipeline across education, post-production and installed sound is now showing signs of recovery.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Genedrive, down 13%. The molecular diagnostics firm expects its full year revenue to be sharply lower but in line with internal guidance. For the year to June 30, Genedrive expects its revenue to come in at GBP1.0 million from GBP2.4 million the year before. Looking ahead, Genedrive said it has received "significant" interest in its 96 SARS-CoV-2 kit, but obtaining regulatory approval is "taking longer than anticipated" and the regulatory agencies the firm is dealing with is "unable to provide definitive timelines for approvals".

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
24 Apr 2024 17:26

Genedrive enters clinical trial deal in US for MT-RNR1 US approval

(Alliance News) - Genedrive PLC on Wednesday said it has entered into a clinical trial agreement to support clinical studies to progress the regulatory approval of its MT-RNR1 product.

Read more
3 Apr 2024 16:54

LONDON MARKET CLOSE: FTSE 100 up thanks to US economic data

(Alliance News) - Stock prices in London closed mostly higher on Wednesday, after some data from the US reinforced the interest rate cut trajectory across the Atlantic.

Read more
3 Apr 2024 13:54

Genedrive shares jump on NICE test recommendation

(Sharecast News) - Genedrive shares were surging on Wednesday, after it received a significant endorsement from the UK's National Institute for Health and Care Excellence (NICE) regarding its 'CYP2C19-ID' test.

Read more
3 Apr 2024 11:49

Genedrive shares surge as UK's NICE backs test for ischaemic stroke

(Alliance News) - Genedrive PLC on Wednesday praised the National Health Service's work on strokes and mini strokes as a test by the company received a recommendation from the UK's National Institute for Health & Care Excellence.

Read more
3 Apr 2024 10:47

AIM WINNERS & LOSERS: UK NICE backs Genedrive test; Corero renews deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
28 Mar 2024 14:35

EARNINGS AND TRADING: 888 advances US exit; Arrow ups reserve estimate

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
15 Mar 2024 14:27

Genedrive receives R&D tax credit, plans fundraise

(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive announced the receipt of a research and development tax credit totalling £0.8m on Friday, taking its unaudited cash balances to £1.2m.

Read more
15 Mar 2024 13:50

Genedrive down as plans equity raise despite GBP800,000 tax credit

(Alliance News) - Genedrive PLC shares fell on Friday, after it said it has received a GBP800,000 research and development tax credit.

Read more
19 Feb 2024 18:57

TRADING UPDATES: Coro seals sale terms, Powerhouse makes good progress

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
19 Feb 2024 10:56

Genedrive set to apply for NICE EVA funding

(Sharecast News) - Genedrive shares rose on Monday, on the launch of the NICE early value assessment (EVA) evidence generation funding call, backed by the National Institute for Health and Care Research (NIHR).

Read more
19 Feb 2024 07:49

LONDON BRIEFING: MoneySupermarket credits Insurance for growth in 2023

(Alliance News) - Stocks in London are set to fall at Monday's open, as concerns over US inflation trends curb risk appetite, and damp hopes of interest rate cuts from the Federal Reserve.

Read more
2 Jan 2024 14:39

Genedrive confirms £0.6m equity prepayment drawdown

(Sharecast News) - Genedrive confirmed a planned £0.6m drawdown as part of its £5m equity prepayment facility on Tuesday, which it initially disclosed on 31 March 2023.

Read more
2 Jan 2024 10:57

IN BRIEF: Genedrive draws down GBP600,000 on prepayment facility

Genedrive PLC - Manchester, England-based molecular diagnostics company - Draws down GBP600,000 on its GBP5 million equity prepayment facility. In March last year, Genedrive agreed the GBP5 million equity prepayment facility with Riverfort Global Opportunities PCC Ltd. At the time it said that proceeds would be used towards the commercialisation of the antibiotic-induced hearing loss test, Genedrive MT-RNR1 ID Kit, and enhancing the Genedrive platform as well as providing additional working capital.

Read more
22 Dec 2023 15:50

UK shareholder meetings calendar - next 7 days

Monday 25 December 
no events scheduled 
Tuesday 26 December 
no events scheduled 
Wednesday 27 December 
Tremor International LtdAGM
Thursday 28 December 
ADVFN PLCAGM
Altona Rare Earths PLCAGM
Beximco Pharmaceuticals LtdAGM
Global Petroleum LtdAGM
Visum Technologies PLCAGM
Friday 29 December 
Apollon Formularies PLCAGM
Eco Atlantic Oil & Gas LtdAGM
Genedrive PLCAGM
Goldplat PLCAGM
Lansdowne Oil & Gas PLCGM re capital raise
Marula Mining PLCAGM
Microsaic Systems PLCGM re fundraise
Online Blockchain PLCAGM
Secure Property Development & Investment PLCAGM
SkinBioTherapeutics PLCAGM
Tetragon Financial Group LtdAGM
Woodbois LtdAGM
Zambeef Products PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
20 Dec 2023 13:57

Genedrive gets first product orders from several countries

(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive has received its first orders for Genedrive MT-RNR1 products from several countries, it announced on Wednesday, including France, Austria, Greece, Saudi Arabia, Turkey, and the Netherlands.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.